Edwards Lifesciences Corporatio (EW) Stock Price & How to Invest

Edwards Lifesciences designs and sells devices that treat structural heart disease, conditions where the heart's valves are damaged or diseased. Its largest business is TAVR, a minimally invasive procedure that replaces a narrowed aortic valve with the SAPIEN valve delivered through a catheter rather than open-heart surgery; TAVR generated about $4.49 billion in 2025, roughly three-quarters of company sales. The company also sells transcatheter mitral and tricuspid therapies (TMTT) such as the PASCAL repair system, EVOQUE tricuspid valve, and SAPIEN M3 mitral system, plus traditional surgical heart valves and supporting technologies. Edwards makes money by selling these high-margin implantable devices to hospitals worldwide, supported by clinical evidence and physician training that reinforce its leadership.

Edwards was spun off from Baxter International in 2000 and became a pure-play structural heart company in 2024 when it divested its Critical Care monitoring business to Becton Dickinson (BD) for roughly $4.2 billion, sharpening its focus on transcatheter heart valves. Recent developments include the EARLY TAVR trial supporting treatment of asymptomatic severe aortic stenosis patients, with Edwards working toward an expanded FDA label, and about $1.2 billion of acquisitions (JenaValve for aortic regurgitation and Endotronix for heart-failure monitoring). TMTT grew more than 56% in 2025 to about $551 million, and the company has returned cash through share buybacks rather than a dividend.

Edwards faces several headwinds at once. TAVR growth has decelerated as the aortic-stenosis market matures, and competition from Medtronic's Evolut platform and Abbott's Navitor could erode share even after Boston Scientific's exit. Much of the business depends on favorable reimbursement and FDA decisions, so a delayed or narrowed label expansion (such as for asymptomatic patients) would hurt the growth story. The stock typically trades at a premium multiple, often well above the broad market, which leaves little margin for error if results disappoint. Finally, integrating acquisitions like JenaValve and Endotronix carries execution risk and may pressure near-term margins before the pipeline pays off.

26 analysts publish price targets on EW, averaging $100.96 against a $86.07 price as of August 2026, or +17.3%. The published targets run from $84.00 to $110.00, a narrow spread, and the ratings split 21 buy, 7 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full EW forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Edwards Lifesciences Corporatio. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. TAVR leadership and label expansion. TAVR remains the core franchise, generating about $4.49 billion in 2025, up roughly 9.3% year over year, and Edwards held an estimated low-70s percent share of the U.S. The most optimistic published target, $110.00, assumes this works close to its best case.

The case against. Edwards faces several headwinds at once. The most pessimistic target, $84.00, is roughly what EW is worth if this bites instead.

Read the full bull and bear case on EW, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Edwards Lifesciences Corporatio's investor relations page or your broker.

• Total revenue (FY2025): ~$6.07 billion, up ~11.5%
• TAVR sales (FY2025): ~$4.49 billion, up ~9.3%
• TMTT growth (FY2025): ~+56%, to ~$551 million
• Adjusted EPS (FY2025): ~$2.56 to $2.62 range
• Gross margin: ~78%
• Market cap: ~$48 to $52 billion
• P/E ratio: ~36x to 49x (varies by basis)

Reading a high-quality medtech like Edwards means weighing durable growth and very high gross margins against a premium valuation. The market has historically paid a P/E well above the broad market for Edwards because of its structural-heart leadership and recurring procedure-driven demand. That premium cuts both ways: when growth stays strong the multiple looks justified, but any deceleration in TAVR or a TMTT stumble can compress the multiple quickly. Because Edwards pays no dividend, total return depends on revenue and earnings growth plus buybacks rather than income.

Other names that sit close to EW: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get EW exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so EW sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where EW fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Edwards Lifesciences is the dominant player in structural heart therapy, anchored by its market-leading SAPIEN TAVR franchise and a rapidly scaling transcatheter mitral and tricuspid business. It tends to behave like a large-cap, high-quality medtech compound: durable double-digit-ish growth, very high gross margins, and a premium multiple that makes the stock sensitive to any sign of decelerating growth.

Whether EW is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EW a buy or a sell?, and where the stock could go from here in the EW stock forecast.

For income investors, whether EW pays a dividend and how the payout looks is covered in does EW pay a dividend? And to weigh EW against a peer, read the full side-by-side comparisons: EW vs MDT and EW vs ABT.